98%
921
2 minutes
20
Background: It is important to evaluate how medication for opioid use disorder (MOUD) implementation interventions impact downstream outcomes, however little is known about impact on hospitalization and emergency department (ED) utilization. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) is a national United States Veterans Health Administration (VHA) effort initially implemented at 18 facilities that increased MOUD receipt in primary care, mental health, and pain clinics. This evaluation assessed SCOUTT's impact on hospitalization and ED utilization.
Methods: This evaluation used a controlled interrupted time series analysis. We extracted electronic health record data for patients with OUD and ≥ 1 visit in an intervention clinic (N = 35) or matched comparison clinic (N = 35) in the post-implementation year. We examined monthly measures of hospitalization and ED utilization in the pre-implementation (9/1/2017-8/31/2018) and post-implementation (9/1/2018-8/31/2019) years. Segmented regression models estimated pre-post immediate and trend changes in intervention relative to comparison clinics, adjusting for pre-implementation trends and patient characteristics. Sensitivity analyses were conducted among patients with ≥ 1 visit in both the pre-/post-implementation years, and post-hoc secondary analyses were conducted among patients with OUD and ≥ 1 other SUD vs. OUD only.
Results: Patients with OUD in both intervention (N = 7,488) and comparison (N = 7,558) clinics had a mean age of 53 years, and the majority were male, White, and not married. During the pre-implementation period, hospitalization and ED utilization increased over time in both intervention and comparison clinics; during the post-implementation period, hospitalization and ED utilization decreased over time in intervention clinics and remained stable in comparison clinics. There was no significant difference in pre-post changes between intervention and comparison clinics for most analyses. In sensitivity analyses the pre-to-post decrease in monthly trend for ED visits was larger in intervention clinics and, in secondary analyses, the pre-to-post decrease in monthly trend for hospitalizations was larger in intervention clinics among patients with OUD and ≥ 1 other SUD.
Conclusions: This evaluation did not find evidence that SCOUTT substantially impacted hospitalization or ED utilization relative to comparison clinics, though there may have been positive impacts for patients with longer engagement in SCOUTT clinics and patients with OUD and ≥ 1 other SUD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938673 | PMC |
http://dx.doi.org/10.1186/s12888-025-06722-6 | DOI Listing |
Nat Genet
September 2025
Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Despite advances in genomic diagnostics, the majority of individuals with rare diseases remain without a confirmed genetic diagnosis. The rapid emergence of advanced omics technologies, such as long-read genome sequencing, optical genome mapping and multiomic profiling, has improved diagnostic yield but also substantially increased analytical and interpretational complexity. Addressing this complexity requires systematic multidisciplinary collaboration, as recently demonstrated by targeted diagnostic workshops.
View Article and Find Full Text PDFCochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDFInnov Aging
August 2025
Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island, United States.
Background And Objectives: Increased referrals to skilled nursing facilities (SNFs) from hospitalized people with opioid use disorder (OUD) carry risk for financial, safety, and legal consequences for poor transitions in care. We aimed to better understand the hospital to SNF referral process and identify opportunities to improve transitions and care for people with OUD, an increasing share of whom are older adults.
Research Design And Methods: Participants included administrative, executive leadership, and clinical staff involved in SNF admission decisions across the United States.
Drug Alcohol Depend Rep
September 2025
Center for Behavioral Emergency and Addiction Research, McWilliams School of Biomedical Informatics, The University of Texas Health Sciences Center at Houston (UTHealth), Houston, TX, United States.
Introduction: As the prevalence of opioid use disorder (OUD) continues to rise, early detection by medical professionals can often be the first step in linking individuals to treatment. This systematic review was designed to identify implemented OUD screening and assessment tools with studies published from January 2019 through June 2024, uncover common themes associated with implementation, and determine if these tools were recommended in clinical practice.
Methods: A systematic literature search was conducted within PubMed, EMBASE, and Web of Science using the keywords 'opioid use disorder,' 'documentation,' and 'screening assessment tool.
Unlabelled: Policy Points Among patients with chronic noncancer pain, state medical cannabis laws did not impact health care use for opioid use disorder. There were no changes in health care use for opioid overdose attributable to medical cannabis laws. Medical cannabis laws do not appear to lead to reductions in adverse opioid-related outcomes.
View Article and Find Full Text PDF